Takeda Low-Dose TAK-475 Trials to Continue; Lifts Stock (Japan)
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals has announced it will continue drug trials of its experimental cholesterol treatment TAK-475. The announcement comes on the heels of a U.S. Food and Drug Administration recommendation that the company stop using high doses of the drug in trials. The decision stemmed from concerns that high doses of the drug may cause liver damage. As a result, the company's stock took a serious downturn, falling 10 percent on Oct. 30. In response, Takeda announced it would remove the 100 mg dose of TAK-475 from trials but continue with the 50 mg dose. Industry insiders say this clarification could put the company's shares back on the rise. (Click here for more - May Require Paid Subscription
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.